Gapping up
In reaction to strong earnings/guidance: CIEN +9.5%, JOY +8.9%, MGCD +8.8%, DCI +6.7%, GWRE +3.5%, LB +2%, (May same store sales were flat vs -3.5%e) OLLI +1.1%, SMTC +0.8%
Select financial related names showing strength: BCS +2.2%, ING +2.2%, DB +1.9%, HSBC +1.5%, PUK +0.9%, .
Other news: RPRX +20.1% (remains on track for MAA submission for enclomiphene for the treatment of secondary hypogonadism with anticipated registration decision expected fall 2017), PPHM +17.5% (highlights latest developments for contract manufacturing and drug development), XGTI +10.4% (continued volatility in pre-mkt trade), AKAO +9.5% (receives $20 mln for an additional option on its existing contract with the Barda to 'support' the development of plazomicin & announces $25 mln private placement to new investors), KERX +5.9% (Baupost Group shows 42.53% active stake following conversion of $125 mln aggregate principal amount of notes), DERM +4.7% (announces topline results from its Phase 3 ATMOS-1 and ATMOS-2 pivotal trials for DRM04; DRM04 demonstrated statistically significant improvements for both co-primary endpoints and both secondary endpoints compared to vehicle), KITE +2.2% (granted access to the Priority Medicines regulatory initiative for KTE-C19 in the treatment of patients with refractory diffuse large B-cell lymphoma ), CCE +2.1% (cont strength), NVS+0.6% (receives EU approval for Afinitor)
Analyst comments: PSTG +4.6% (upgraded to Buy from Neutral at UBS), OPHT +4.4% (upgraded to Overweight from Neutral at JP Morgan), PENN +1.6% (upgraded to Equal-Weight from Underweight at Morgan Stanley), NVDA +0.5% (initiated with a Buy at Goldman)
In reaction to strong earnings/guidance: CIEN +9.5%, JOY +8.9%, MGCD +8.8%, DCI +6.7%, GWRE +3.5%, LB +2%, (May same store sales were flat vs -3.5%e) OLLI +1.1%, SMTC +0.8%
Select financial related names showing strength: BCS +2.2%, ING +2.2%, DB +1.9%, HSBC +1.5%, PUK +0.9%, .
Other news: RPRX +20.1% (remains on track for MAA submission for enclomiphene for the treatment of secondary hypogonadism with anticipated registration decision expected fall 2017), PPHM +17.5% (highlights latest developments for contract manufacturing and drug development), XGTI +10.4% (continued volatility in pre-mkt trade), AKAO +9.5% (receives $20 mln for an additional option on its existing contract with the Barda to 'support' the development of plazomicin & announces $25 mln private placement to new investors), KERX +5.9% (Baupost Group shows 42.53% active stake following conversion of $125 mln aggregate principal amount of notes), DERM +4.7% (announces topline results from its Phase 3 ATMOS-1 and ATMOS-2 pivotal trials for DRM04; DRM04 demonstrated statistically significant improvements for both co-primary endpoints and both secondary endpoints compared to vehicle), KITE +2.2% (granted access to the Priority Medicines regulatory initiative for KTE-C19 in the treatment of patients with refractory diffuse large B-cell lymphoma ), CCE +2.1% (cont strength), NVS+0.6% (receives EU approval for Afinitor)
Analyst comments: PSTG +4.6% (upgraded to Buy from Neutral at UBS), OPHT +4.4% (upgraded to Overweight from Neutral at JP Morgan), PENN +1.6% (upgraded to Equal-Weight from Underweight at Morgan Stanley), NVDA +0.5% (initiated with a Buy at Goldman)